HP Pyruvate MRI in Cancers

Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-88
SponsorUniversity of Maryland, Baltimore

About this trial

Many human diseases are characterized by their ability to alter existing metabolic pathways and interrupt cellular processes. Cancer exploits the Warburg effect and utilizes greater glucose than normal cells and within this process uses anaerobic respiration, leading to increased conversion of pyruvate to lactate. This can be exploited by hyperpolarized imaging. Hyperpolarized 13C MRI imaging is an approach that utilizes a stable isotope of Carbon (13C) linked to pyruvate. MRI spectroscopy is used in conjunction with hyperpolarized 13C pyruvate in order to temporally detect pyruvate and its conversion to lactate in-vivo, in order to visualize downstream metabolic (glycolytic) activity secondary to the Warburg effect, which should be useful in detecting and characterizing tumors of various types. Hyperpolarized 13C pyruvate MR imaging has not been tested in most cancers. In this preliminary survey, we will test the hypothesis that hyperpolarized 13C pyruvate MR imaging can be used to image various cancers.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Single group

Treatments tested in this trial

  • Hyperpolarized 13C-Pyruvate

    Drug

    Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.

Treatment groups

25 Participants
are divided into 1 treatment group
Group A: ExperimentalExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Pyruvate to Lactate Conversion

Imaging Quality, KpL

Time frame
18-36 months

Secondary outcomes

1

SNR

Signal to Noise Ratio, dB

Time frame
12-42 months
2

CNR

Contrast to Noise

Time frame
12-42 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.